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The signaling lipid sphingosine-1-phosphate 
(S1P) plays critical roles in mammalian biology. 
Extracellular S1P binds five G protein–coupled 
receptors, S1P receptors 1–5 (Hla, 2004), and 
intracellular S1P binds an expanding set of pro-
teins (Hait et al., 2009; Alvarez et al., 2010; 
Puneet et al., 2010). The concentration of S1P 
is high in circulatory fluids, and plasma S1P sta-
bilizes junctions between vascular endothe-
lial cells (Lee et al., 1999; Kono et al., 2008; 
Camerer et al., 2009). The concentration of ex-
tracellular S1P is low in lymphoid tissues com-
pared with blood and lymph, and this difference 
directs lymphocyte egress from lymphoid organs 
into circulation (Schwab and Cyster, 2007). 
Although extracellular S1P in lymphoid organs, 
and likely most tissues, is low in homeostasis, 
S1P may increase upon inflammation. Elevated 
S1P has been reported to promote angiogenesis 
and to enhance proinflammatory responses of 
innate and adaptive immune cells (Rivera et al., 
2008; Liu et al., 2010). Drugs targeting S1P signal-
ing are in clinical trials as immune suppressants 
(Carroll, 2010). In fact, FTY720 has just been 
approved by the United States Food and Drug 
Administration for treatment of multiple scle-
rosis (Brinkmann et al., 2010). By blocking exit 
from lymphoid organs, these drugs prevent ac-
tivated T cells from trafficking to organs under 
autoimmune attack. These drugs may also have 
direct antiinflammatory effects.
Despite its importance, little is known about 
how the distribution of S1P is controlled in 
vivo. This question is particularly interesting 
because it is difficult to understand how a ubiq-
uitously made lipid functions as a signal that 
requires precise spatial and temporal control. 
To maintain low extracellular tissue S1P in ho-
meostasis, several sources of S1P must be con-
tained. First, all cells are thought to make S1P 
intracellularly as an intermediate in membrane 
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The signaling lipid sphingosine--phosphate (SP) stabilizes the vasculature, directs lym-
phocyte egress from lymphoid organs, and shapes inflammatory responses. However, little is 
known about how SP distribution is controlled in vivo, and it is not clear how a ubiqui-
tously made lipid functions as a signal that requires precise spatial and temporal control. 
We have found that lipid phosphate phosphatase 3 (LPP3) enables efficient export of 
mature T cells from the thymus into circulation, and several lines of evidence suggest that 
LPP3 promotes exit by destroying thymic SP. Although five additional SP-degrading 
enzymes are expressed in the thymus, they cannot compensate for the loss of LPP3. More-
over, conditional deletion of LPP3 in either epithelial cells or endothelial cells is sufficient 
to inhibit egress. These results suggest that SP generation and destruction are tightly 
regulated and that LPP3 is essential to establish the balance.
© 2011 Bréart et al. This article is distributed under the terms of an Attribu-
tion–Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.rupress.org/terms). After six months 
it is available under a Creative Commons License (Attribution–Noncommercial– 
Share Alike 3.0 Unported license, as described at http://creativecommons.org/ 
licenses/by-nc-sa/3.0/).
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of Mx1-Cre mediates efficient deletion in a wide range of 
tissues and lineages, including hematopoietic cells and a sub-
set of endothelial cells (Pappu et al., 2007). For simplicity, 
we refer to pI-pC–treated Ppap2bf/ Mx1Cre+ and Ppap2bf/f 
Mx1Cre+ mice as LPP3 deficient. Littermate controls were 
pI-pC treated at the same time as LPP3-deficient mice and 
retained at least one intact copy of LPP3. To assess whether 
LPP3 regulates thymic S1P, we examined three parameters 
that are dependent on S1P signaling: the rate of exit of mature 
T cells from the thymus, the level of surface CD69 on mature 
thymocytes, and the level of surface S1P receptor 1 (S1PR1) 
on mature thymocytes.
LPP3 deficiency impairs thymic egress
We first asked whether egress of mature T cells from the 
thymus was impaired in LPP3-deficient mice. T cells must 
express S1PR1 to exit lymphoid organs into circulatory fluids 
(Allende et al., 2004; Matloubian et al., 2004; Weinreich and 
Hogquist, 2008). Furthermore, disruption of the S1P gradi-
ent, either by removing circulatory S1P (Pappu et al., 2007) 
or by raising lymphoid tissue S1P (Schwab et al., 2005), blocks 
egress. We expected that if thymic S1P were elevated in the 
absence of LPP3, exit would be slowed, resulting in an accu-
mulation of mature T cells in the thymus.
We observed a 2.5-fold increase in the percentage of 
mature CD4 single-positive (CD4SP) T cells (CD4+CD8 
CD62LhiCD69lo) among total CD4SP (CD4+CD8) thy-
mocytes in LPP3-deficient mice compared with littermate 
controls (Fig. 1, A and B). There is also an increase in the 
percentage of CD4SP T cells among total thymocytes. When 
we calculated absolute numbers, we found a 4.5-fold increase 
of mature CD4SP T cells in the thymus of LPP3-deficient 
mice without any change in the number of immature CD4SP 
precursors (Fig. 1 C). The absolute numbers are more variable 
than the percentages, as the total size of the thymus varies 
with many factors including age and stress. Nonetheless, in 
each case the number of mature CD4SP was larger in the 
LPP3-deficient mouse than its littermate control. We saw no 
change in the number of double-negative (DN) T cells and a 
30% reduction in the number of double-positive (DP) T cells in 
the thymus of LPP3-deficient mice compared with littermate 
controls (Fig. S1 A). As one might predict from a slowing of 
thymic egress, we saw a moderate reduction in the number 
of T cells in the periphery (Fig. S1 B). Mature CD8 single-
positive T cells similarly accumulate in the thymus of LPP3-
deficient mice (Fig. S1 C).
The accumulation of mature T cells suggests an egress 
block but could also result from enhanced proliferation of 
mature T cells. Developing T cells mature from the DN to the 
DP to the SP stage. In WT mice, thymocytes proliferate 
extensively as they transition from DN to DP and relatively 
infrequently at the SP stage (Egerton et al., 1990). To assess the 
possibility that mature SP T cells divide more frequently in 
LPP3-deficient mice, we treated mice continuously with the 
thymidine analogue BrdU in the drinking water to label pro-
liferating cells. After 11 d of BrdU treatment, virtually all 
sphingolipid metabolism (Hannun and Obeid, 2008); meta-
bolic S1P must be destroyed before it accumulates in the 
interstitial space. Second, plasma S1P must be excluded from 
the tissue. S1P concentrations in plasma are in the micromolar 
range, and although tissues are constantly bathed with transu-
dated plasma to bring nutrients and remove waste, S1P in the 
interstitial fluid of lymphoid organs has been estimated to be 
sub-nanomolar (Schwab and Cyster, 2007). S1P’s abundance 
suggests the possibility that levels could be changed rapidly in 
response to physiological cues and the requirement that its 
concentration be tightly regulated.
Many factors are undoubtedly required to maintain low 
tissue S1P, but one key is likely how S1P is degraded. Strik-
ingly, not one but six enzymes are known to destroy S1P in 
vitro. These enzymes fall into two classes. The first consists of 
S1P lyase, which cleaves S1P to 2-hexadecenal and phospho-
ethanolamine, and S1P phosphatases 1 and 2, which dephos-
phorylate S1P to sphingosine (Saba and Hla, 2004). These 
three enzymes are thought to be highly specific for S1P and 
reside predominantly in the endoplasmic reticulum. S1P lyase 
is required to maintain low lymphoid organ S1P (Schwab et al., 
2005). Although the source of S1P destroyed by S1P lyase is 
not known, it is likely to be S1P made in the course of sphin-
golipid metabolism; S1P lyase’s intracellular location positions 
it well for this function. The second class of S1P-degrading 
enzymes consists of three phosphatases: lipid phosphate phos-
phatases 1, 2, and 3 (Roberts et al., 1998; Brindley et al., 2000; 
Pyne et al., 2004). These enzymes can dephosphorylate a 
range of substrates, including S1P, ceramide-1-phosphate, 
lysophosphatidic acid, and phosphatidic acid. The lipid phos-
phate phosphatases have been shown in many cell types to 
localize to the plasma membrane with their active site facing 
outside the cell, well positioned to degrade extracellular lipid 
entering the tissues from the blood or secreted by tissue-resident 
cells. The role of the lipid phosphate phosphatases in control-
ling tissue S1P is largely unknown.
In this paper, we asked what is the role of lipid phosphate 
phosphatase 3 (LPP3; encoded by Ppap2b) in regulating extra-
cellular S1P within lymphoid organs. We found that LPP3 is 
essential to enable efficient export of mature T cells from the 
thymus to the blood, and several lines of evidence suggest that 
LPP3 promotes egress by maintaining low thymic S1P. Although 
all six S1P-degrading enzymes are expressed in the thymus, 
the loss of LPP3 alone in either epithelial cells or endothelial 
cells is sufficient to delay exit.
RESULTS
LPP3 is required to keep thymic SP low
Because LPP3 is essential in embryonic development (Escalante-
Alcalde et al., 2003), we used Ppap2bf/f mice to study the func-
tion of LPP3 in lymphoid organs (Escalante-Alcalde et al., 
2007). We crossed in Cre recombinase driven by the inter-
feron-inducible Mx1 promoter (Mx1-Cre; Kühn et al., 1995). 
Pups were treated with polyinosinic:polycytidylic acid (pI-pC) 
3–5 d after birth to activate the Mx1 promoter and Cre expres-
sion. Adults were analyzed at least 6 wk later. This induction 
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consistent with prolonged thymic residence and delayed egress 
but not with reentry of peripheral T cells.
Finally, we directly tested the efficiency of thymic egress 
by injecting sulfo-NHS biotin into the thymus of LPP3- 
deficient mice and littermate controls and tracking the 
appearance of labeled cells in the periphery. To minimize 
inflammation, we used ultrasound to guide the injection needle 
(Blair-Handon et al., 2010). After 16 h, we found that the 
ratio of labeled CD4+ T cells in the periphery (pooled blood, 
spleen, and LNs) to labeled mature CD4SP T cells remaining 
in the thymus was 0.2 in LPP3-deficient mice and 1.3 in con-
trols (Fig. 1 F). Approximately twofold fewer labeled cells had 
emigrated to the periphery in LPP3-deficient mice, whereas 
threefold more labeled cells stayed in the thymus. These 
results are again consistent with an exit defect.
LPP3 deficiency causes down-modulation of CD69  
on mature T cells
Our second indication that LPP3 regulates thymic S1P was 
the level of the activation marker CD69 on mature SP thy-
mocytes. Mature SP T cells normally express intermediate levels 
of CD69, as they have recently completed positive selection, 
but S1P signaling causes rapid down-modulation of surface 
CD69. This observation was first made in mice treated with 
the S1P receptor agonist AAL-(R) (Rosen et al., 2003) and 
mature CD4SP T cells in control mice were BrdU+ (Fig. 1 D). 
In contrast, in LPP3-deficient mice a substantial number of 
mature CD4SP T cells remained unlabeled (Fig. 1 D). The in-
creased fraction of BrdU mature SP T cells is inconsistent 
with enhanced proliferation of mature SP thymocytes in LPP3-
deficient mice. Instead, it is consistent with delayed egress; the 
BrdU cells likely developed before the labeling period began 
and remained in the thymus for an extended period. Mature 
CD8SP T cells had a similar pattern (Fig. S1 D).
Although an accumulation of mature T cells in the absence 
of proliferation is consistent with a failure to exit, it is also 
possible that this could reflect enhanced reentry of peripheral 
T cells into the thymus. To distinguish between these possi-
bilities, we took advantage of Rag2p-GFP reporter mice (Yu 
et al., 1999; Boursalian et al., 2004). In these mice, GFP tran-
scription is driven by the Rag2 promoter. After RAG is turned 
off at the DP stage, GFP protein levels decay with a half-life 
of 56 h (McCaughtry et al., 2007). GFP acts as a clock, with 
its abundance reflecting the amount of time that has passed 
since positive selection. Analysis of LPP3-deficient Rag2p-
GFP+ mice and Rag2p-GFP+ littermate controls revealed that 
mature CD4SP LPP3-deficient thymocytes have lower GFP 
than mature CD4SP control thymocytes but higher GFP than 
naive CD4 T cells circulating in the periphery (Fig. 1 E). Mature 
CD8SP T cells behave similarly (Fig. S1 E). This pattern is 
Figure . LPP3 is required for efficient thymic egress. 
LPP3-deficient mice (; Ppap2bf/Mx1Cre+ or Ppap2bf/f 
Mx1Cre+, treated with pI-pC 3–5 d after birth) and littermate 
controls (F; Ppap2bf/+Mx1Cre+, Ppap2b+/Mx1Cre+, 
Ppap2bf/, Ppap2bf/f, Ppap2bf/+, or Ppap2b+/, treated with 
pI-pC 3–5 d after birth at the same time as LPP3-deficient 
mice) were analyzed at 6 wk or older. (A) Expression of CD4 
and CD8 by total thymocytes (top) and expression of CD69 
and CD62L by CD4SP (CD4+CD8) thymocytes (bottom) from 
a representative LPP3-deficient mouse () and littermate 
control (F). (B) Percentage of mature CD4SP thymocytes 
(CD4+CD8CD62LhiCD69lo) among total CD4SP thymocytes. 
(C) Total number of mature CD4SP thymocytes and imma-
ture CD4SP thymocytes (CD4+CD8CD62LloCD69hi). In B and 
C, each point represents an individual mouse and bars show 
the mean. Graphs are a compilation of 13 experiments with 
a total of 21 mice per group. In all figures, p-values were 
calculated using the two-tailed unpaired Student’s t test.  
(D) LPP3-deficient mice and littermate controls were treated 
with 0.8 mg/ml BrdU in the drinking water for 11 d. BrdU 
incorporation by mature CD4SP thymocytes, as well as naive 
blood CD4+ T cells, was measured by flow cytometry. Data 
are representative of three pairs of mice analyzed in three 
experiments. (E) GFP levels of mature CD4SP thymocytes 
from a representative Rag2p-GFP+ LPP3-deficient () mouse, 
mature CD4SP thymocytes from its Rag2p-GFP+ littermate 
control (F), and naive (CD69LhiCD69lo) CD4+ T cells from the blood of the LPP3-deficient Rag2p-GFP+ mouse, measured by flow cytometry. Data are repre-
sentative of four pairs of mice analyzed in two experiments. (F) Sulfo-NHS biotin was injected into the thymus of LPP3-deficient mice and littermate con-
trols. 16 h later, biotin-labeled mature CD4SP T cells in the thymus and CD4+ T cells in the periphery (combined blood, spleen, mesenteric, inguinal, 
axillary, and brachial LNs) were enumerated. The graph shows the ratio of the number of labeled cells in the periphery to the number of labeled cells re-
maining in the thymus. Each point represents an individual mouse and bars show the mean. The graph compiles data from seven LPP3-deficient mice and 
four littermate controls analyzed in two experiments. Mature T cells in the thymus of LPP3-deficient and littermate controls were labeled with similar 
efficiency (mean 57 and 62%, respectively).
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elevated thymic S1P, surface S1PR1 on thymic T cells 
would be reduced.
We found that the level of S1PR1 is two- to threefold 
lower on the surface of mature SP thymocytes of LPP3-deficient 
mice than littermate controls (Fig. 2 D). S1pr1 transcript is 
comparable between LPP3-deficient and littermate control mice, 
suggesting that the decrease is posttranscriptional (Fig. S2 A). 
CCR7 surface protein also does not differ between LPP3-
deficient and littermate control mice, suggesting that the 
decrease does not reflect a global down-modulation of G 
protein–coupled receptors (Fig. S2 B).
Collectively, the egress block, CD69 down-modulation, and 
reduction in surface S1PR1 strongly suggest that the S1P-
degrading enzyme LPP3 is required to maintain low thymic 
S1P. Using mass spectrometry, we were unable to detect ele-
vated S1P in whole thymic tissue of LPP3-deficient mice 
(Fig. S2C), which is not surprising given the incomplete 
down-modulation of S1PR1. The concentration of S1P in the 
thymus of control animals is 0.5 pmol/mg wet weight, which 
translates to 500 nM assuming that the density of the thymus 
is the same as water (an underestimate). This is consistent with 
previous measurements of S1P in the whole embryo (Mizugishi 
et al., 2005). In contrast to the total level of S1P in the thymus, 
10 nM of extracellular S1P is sufficient to decrease surface 
S1PR1 on mature thymocytes to below our limit of detection 
(Schwab et al., 2005). The S1P measured by mass spectrometry 
of whole thymic tissue is largely inaccessible to S1P receptors, 
consistent with S1P’s role as an intracellular metabolic interme-
diate. Against the variability of our measurements of S1P in 
control thymus, we are unable to detect an increase in extracel-
lular S1P that causes partial receptor internalization.
LPP3 is required in radiation-resistant cells
To determine which cell type requires LPP3 to maintain 
low thymic S1P, we began by generating BM chimeras. 
reproduced in mice treated with the S1PR1-selective agonist 
SEW2871 (Alfonso et al., 2006). CD69 and S1PR1 interact, 
and S1PR1 mediates CD69 internalization in a pertussis toxin–
sensitive manner (Shiow et al., 2006). CD69 is down-modulated 
on mature but not immature SP T cells. S1pr1 mRNA is 
>10-fold more abundant in mature than in immature CD4SP 
thymocytes (Matloubian et al., 2004), and surface S1PR1 
protein is readily detectable on mature but not immature SP 
T cells (Zachariah and Cyster, 2010). We expected that if S1P 
were elevated in the thymus of LPP3-deficient mice, surface 
CD69 on mature SP T cells would decrease.
We observed down-modulation of CD69 on the surface 
of mature SP T cells in LPP3-deficient animals compared 
with littermate controls (Fig. 1 A). To pool experiments, we 
calculated the ratio of CD69 mean fluorescence intensity 
(MFI) of littermate control mature CD4SP thymocytes/
CD69 MFI of LPP3-deficient mature CD4SP thymocytes. 
This ratio was 3 (Fig. 2 A). The down-modulation of CD69 
on mature T cells in LPP3-deficient mice is not simply sec-
ondary to a longer residence time, as it was also seen on the 
recently mature GFPhi cells in LPP3-deficient Rag2p-GFP+ 
mice (Fig. 2 B). The decreased CD69 on mature T cells is also 
not the result of a failure to up-regulate fully CD69 during 
positive selection, as we saw no difference in the level of CD69 
on immature CD4SP T cells from LPP3-deficient mice and 
littermate controls (Figs. 1 A and 2 C).
LPP3 deficiency causes internalization of SPR
Our third test of whether LPP3 is required to maintain 
low extracellular thymic S1P was the level of surface 
S1PR1 on mature SP T cells. Mature SP T cells normally 
express abundant S1PR1, enabling them to exit the thy-
mus efficiently (Matloubian et al., 2004). S1PR1 is inter-
nalized upon binding S1P (Liu et al., 1999; Schwab et al., 
2005), and we expected that if LPP3-deficient mice had 
Figure . LPP3 deficiency causes down-
modulation of CD69 and SPR. (A) The 
ratio of CD69 MFI of mature CD4SP thymo-
cytes from littermate controls (F)/CD69 MFI of 
mature CD4SP thymocytes from LPP3- 
deficient mice (). Each point represents one 
pair of mice, and the bar represents the mean. 
The graph compiles 13 experiments with a 
total of 21 pairs of mice. (B) Dot plots (left) 
show expression of GFP versus forward scat-
ter (FSC) by mature CD4SP T cells from a rep-
resentative Rag2p-GFP+ LPP3-deficient mouse 
() and Rag2p-GFP+ littermate control (F), 
and they indicate the GFPhi gate. The GFP MFI 
within the GFPhi gate differs by <10% be-
tween littermate controls and LPP3-deficient 
mice. The bar graph (right) shows the ratio of CD69 MFI of GFPhi mature CD4SP thymocytes from Rag2p-GFP+ littermate controls/CD69 MFI of GFPhi ma-
ture CD4SP thymocytes from Rag2p-GFP+ LPP3-deficient mice. Each point represents one pair of mice, and each bar represents the mean. The graph 
compiles data from four pairs of mice analyzed in two experiments. (C) The ratio of CD69 MFI of immature CD4SP thymocytes from littermate controls 
(F)/CD69 MFI of immature CD4SP thymocytes from LPP3-deficient mice (). Each point represents one pair of mice, and each bar represents the mean. 
The graph compiles six experiments with a total of eight pairs of mice. (D) Surface S1PR1 levels on mature CD4SP thymocytes. The thin line shows stain-
ing with a control antibody. Data are representative of three pairs of mice analyzed in three experiments.
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LPP3 is expressed by multiple radiation-resistant cell types
To determine which radiation-resistant cell type must ex-
press LPP3 to maintain low thymic S1P, we began by asking 
which cells express Ppap2b mRNA using quantitative PCR 
on sorted cells from WT mice. Consistent with the importance 
of LPP3 on radiation-resistant cells, we found that Ppap2b 
mRNA is enriched 100-fold in CD45 thymic stroma com-
pared with T cells. However, there are no dramatic differences 
in expression between EpCAM+ epithelial cells, CD31+ en-
dothelial cells, and other CD45 stromal cells (Fig. 4 A). We 
also asked whether any of these cell types differ in expression 
of the other five S1P-degrading enzymes, suggesting that they 
might be uniquely dependent on LPP3. We found that LPP1 
(Ppap2a) and LPP2 (Ppap2c) have a similar pattern to LPP3 
(Fig. 4 A) and that the S1P-specific enzymes S1P lyase (Spgl1), 
S1P phosphatase 1 (SPP1; Sgpp1), and SPP2 (Sgpp2) are also 
expressed by all subsets of radiation-resistant cells (Fig. 4 B).
Our next attempt to narrow down the cell type that must 
express LPP3 was to ask whether Mx1-Cre deletes preferen-
tially in any radiation-resistant cell types in the thymus. We 
crossed mice expressing Mx1-Cre with an enhanced (E) YFP 
reporter strain, R26R-EYFP, which has EYFP in the ubiqui-
tously expressed Rosa26 locus preceded by a floxed transcrip-
tional stop (Srinivas et al., 2001), treated the pups with pI-pC 
at 3–5 d after birth, and analyzed the mice as adults. Analysis 
of disaggregated thymocytes by flow cytometry revealed de-
letion in approximately two thirds of epithelial cells, one third 
of endothelial cells, and 10% of other stroma, as well as >90% 
of hematopoietic cells (Fig. 4 C). Because the strong YFP ex-
pression by lymphocytes obscured analysis of YFP expression 
by radiation-resistant cells using confocal microscopy, we also 
reconstituted lethally irradiated adults with WT BM. Analysis 
of thymic sections from the chimeras confirmed that Mx1-
Cre deletes in multiple radiation-resistant cell types, including 
epithelial cells and endothelial cells (Fig. 4 D).
Staining of frozen thymic sections with an antibody to 
LPP3 revealed robust protein expression by medullary epithe-
lial cells, which was largely absent in LPP3-deficient mice 
(Fig. 4 E). LPP3 seemed to ring the endothelial wall of blood 
vessels, consistent with results showing that LPP3 localizes to 
the basolateral side of cultured MDCK cells (Jia et al., 2003). 
This staining was less frequent in LPP3-deficient mice (Fig. 4 E). 
LPP3 protein was also expressed by a range of other stromal 
cells, likely including pericytes (Fig. S4).
LPP3 is required in both endothelial cells and epithelial cells
We then began a candidate approach to determine which cell 
type must express LPP3. Because we observed high expression 
of LPP3 by endothelial cells and partial deletion in endothe-
lial cells by Mx1-Cre, and because endothelial cells sit at the 
border of the high S1P environment of the blood and the 
low S1P environment of the thymus, we considered the pos-
sibility that LPP3 was required in endothelial cells to maintain 
low thymic S1P. To delete LPP3 in vascular endothelial cells, 
we crossed Ppap2bf/f mice with mice carrying Cre recombi-
nase driven by the Tie2 promoter (Kisanuki et al., 2001). 
We observed no difference between lethally irradiated WT 
mice reconstituted with LPP3-deficient BM and mice recon-
stituted with littermate control BM (Fig. S3, A–E). However, 
when we compared lethally irradiated LPP3-deficient and 
littermate control mice reconstituted with WT BM, we found 
a striking difference. WT mature SP thymocytes in LPP3- 
deficient animals have a fivefold accumulation (Fig. 3, A and B), 
a decrease in CD69 (Fig. 3, C and D), and a two- to threefold 
decrease in S1PR1 (Fig. 3 E). This suggests that LPP3 is re-
quired in radiation-resistant cells to maintain low thymic S1P. 
It is interesting to note that this pattern contrasts with that of 
S1P lyase, which is required in hematopoietic cells to main-
tain low lymphoid S1P (Schwab et al., 2005; lyase expression 
by stromal cells is likely also important). Treatment of LPP3-
deficient mice with the S1P lyase inhibitor deoxypyridoxine-
HCl further increases thymic S1P (Fig. S3 F).
Figure 3. LPP3 is required in radiation-resistant cells to maintain 
low thymic SP. CD45.2+ LPP3-deficient () mice and littermate controls 
(F) were lethally irradiated and reconstituted with CD45.1+ WT BM. The 
chimeras were analyzed 7–10 wk later. All analyses are gated on WT thy-
mocytes (94–99% of total). (A) Percentage of mature CD4SP thymocytes 
among total CD4SP thymocytes. (B) Total number of mature CD4SP thy-
mocytes and immature CD4SP thymocytes. In A and B, each point repre-
sents an individual mouse and bars show the mean. Graphs are a 
compilation of four experiments with a total of 10–11 mice per group.  
(C) Expression of CD69 and CD62L on CD4SP thymocytes. (D) The ratio of 
CD69 MFI of mature CD4SP thymocytes from littermate control chimeras/
CD69 MFI of mature CD4SP thymocytes from LPP3-deficient chimeras. 
Each point represents one pair of mice, and the bar represents the mean. 
The graph compiles 10 pairs of mice analyzed in four experiments.  
(E) Surface S1PR1 expression on mature CD4SP thymocytes. The thin line 
shows staining with a control antibody. Data are representative of three 
pairs of mice analyzed in three experiments.
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periphery of these mice (Fig. S5 B). We observed 
a decrease of surface CD69 on mature T cells, which 
is, again, significant but less dramatic than in mice in 
which deletion was mediated by Mx1-Cre (Fig. 5, 
C and D; CD69 is higher in Ppap2bf/Cdh5(PAC)-
CreERT2+ than in Ppap2bf/ or f/f Mx1Cre+ mice 
with P < 0.01). Finally, we observed at most a slight 
down-modulation of S1PR1 on mature T cells (Fig. 5 E). We 
suspect that down-modulation is difficult to detect as a re-
sult of the relatively mild phenotype and limited sensitivity of 
our antibody.
To determine the pattern of deletion, we crossed mice 
expressing Cdh5(PAC)-CreERT2 with the YFP reporter 
strain. Confocal microscopy of thymic sections revealed spe-
cific deletion in endothelial cells (Fig. 5 F and Fig. S5 A), 
which was confirmed by analysis of disaggregated thymic cells 
by flow cytometry. We saw variable excision, ranging from 20 
to 70%, whereas deletion in other cell types was undetectable 
(Fig. 5 G). It is possible that the intermediate effect of LPP3 
deletion within endothelial cells is a result of incomplete ex-
cision. It is also possible that the loss of LPP3 in endothelial 
cells causes a very small increase in thymic S1P but that 
We had no live-born Ppap2bf/fTie2-Cre+ pups (unpublished 
data), which was not surprising as Ppap2b/ embryos suffer 
severe vascular defects (Escalante-Alcalde et al., 2003). To cir-
cumvent embryonic lethality, we used the inducible CreERT2 
recombinase under the endothelial VE-Cadherin (Cdh5) pro-
moter (Wang et al., 2010). We treated Ppap2bf/Cdh5(PAC)-
CreERT2+ mice, as well as littermate controls, with tamoxifen 
to induce excision.
We saw a twofold accumulation of mature T cells in 
Ppap2bf/Cdh5(PAC)-CreERT2+ mice compared with litter-
mate controls, which is significant but smaller than in mice in 
which deletion was mediated by Mx1-Cre (Fig. 5, A and B; 
the cell number in Ppap2bf/Cdh5(PAC)-CreERT2+ mice is 
less than in Ppap2bf/- or f/f Mx1Cre+ mice with P < 0.01). We 
saw a moderate reduction in the number of T cells in the 
Figure . LPP3 is expressed by multiple radiation-resistant 
cell types. (A and B) Abundance of mRNA transcripts encod-
ing the indicated S1P degrading enzymes, expressed relative to 
Hprt (hypoxanthine-guanine phosphoribosyltransferase) tran-
script, in sorted thymic populations, measured by quantitative 
RT-PCR. Ppap2a, LPP1; Ppap2b, LPP3; Ppap2c, LPP2; Sgpp1, 
SPP1; Sgpp2, SPP2; and Spgl1, S1P lyase. Endothelial cells were 
defined as CD45CD31+, epithelial cells as CD45EpCAM+, 
other stromal cells as CD45CD31EpCAM, and DP T cells as 
CD4+CD8+ (none of the transcripts differ among DP, immature 
CD4SP, or mature CD4SP T cells, not depicted). The point shows 
the mean, and the vertical line shows the standard deviation. 
Data compile three to six experiments with mice on a B6 or a 
B6 × 129 mixed background (the results did not differ by 
strain). Each experiment is a separate cell purification from 
three to four pooled mice, RNA extraction, and quantitative 
RT-PCR. (C) R26R-EYFP+ Mx1Cre+ mice were treated with pI-pC 
3–5 d after birth and analyzed at least 6 wk later. YFP expres-
sion by disaggregated thymic cell populations was measured 
by flow cytometry. CD45+ cells are primarily T cells, as they 
were isolated by mechanical disruption. Each point represents 
an individual mouse, and bars show the mean. The graph com-
piles two mice analyzed in two experiments. (D) R26R-EYFP+ 
Mx1Cre+ mice were treated with pI-pC 3–5 d after birth. Adults 
were lethally irradiated and reconstituted with WT BM. The 
resulting chimeras were analyzed 7–10 wk later. Frozen thymic 
sections were stained for CD31 to mark endothelial cells or 
EpCAM to mark epithelial cells and visualized by confocal  
microscopy. Bars, 20 µm. The image is representative of two 
mice analyzed in two experiments. (E) Frozen thymic sections 
from LPP3-deficient mice and littermate controls were stained 
for CD31 to mark endothelial cells, EpCAM to mark epithelial 
cells, and LPP3 and were visualized by confocal microscopy. 
Bars, 20 µm. The image is representative of two pairs of mice 
analyzed in two experiments.
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Confocal microscopy of thymic sections revealed deletion 
primarily in medullary epithelial cells (Fig. 6 F, Fig. S6 A). 
This pattern was also seen in analysis of disaggregated thy-
mic cells by flow cytometry. We observed excision within 
75% of EpCAM+ cells (Fig. 6 G). We have confirmed a 
requirement for LPP3 in epithelial cells using Ppap2bf/ 
Foxn1-Cre+ mice (Fig. S6, C and D); FoxN1-Cre deletes 
specifically and universally in thymic epithelial cells (Gordon 
et al., 2007).
DISCUSSION
We found that LPP3 is essential to enable efficient thymic 
egress, and several lines of evidence suggest that LPP3 pro-
motes exit by maintaining low thymic S1P. In the absence of 
biochemical evidence of increased S1P, uncertainty remains 
in the interpretation of our results; measurements of total thy-
mic S1P by mass spectrometry are uninformative because the 
background of intracellular S1P (500 nM), combined with 
measurement variability, is too high to detect an increase in 
extracellular S1P predicted to cause partial S1PR1 down-
modulation (<10 nM or 2% of total). Nonetheless, because 
S1P is the only LPP3 substrate that has been implicated in 
egress, CD69 down-modulation, or S1PR1 internalization, 
the elevated S1P is precisely where T cells most need a 
sharp gradient to egress as they cross the blood vessel wall 
into circulation.
Because we also observed high expression of LPP3 by 
thymic epithelial cells and efficient deletion in thymic epithe-
lial cells by Mx1-Cre, we considered the possibility that 
LPP3 was required in these cells. To delete LPP3 in epithelial 
cells, we used the Cre recombinase under the Keratin 14 
promoter (Dassule et al., 2000). We bred Ppap2bf/Krt14-Cre+ 
mice. Littermate controls were Ppap2bf/+Krt14Cre+, Ppap2bf/+, 
or Ppap2bf/.
Mature T cells in the thymus of Ppap2bf/Krt14-Cre+ mice 
have a 3.5-fold accumulation (Fig. 6, A and B), accompanied 
by a small reduction of T cells in the periphery (Fig. S6 B). 
Mature T cells in the thymus of Ppap2bf/Krt14-Cre+ mice 
also display down-modulation of CD69 (Fig. 6, C and D) and 
a twofold decrease in S1PR1 compared with littermate con-
trols (Fig. 6 E).
To determine the pattern of deletion, we crossed mice 
expressing Keratin 14-Cre with the YFP reporter strain. In both 
the LPP3 and YFP reporter crosses, Cre recombinase was 
carried only by the father to avoid potential widespread deletion 
as a result of expression in the oocyte (Hafner et al., 2004). 
Figure . LPP3 expression by endothelial 
cells is required to maintain low thymic 
SP. Mice in which LPP3 was deleted by  
VE-Cadherin-CreERT2 (VE-; Ppap2bf/ 
Cdh5(PAC)-CreERT2+, treated with tamoxifen 
at 3–4 wk old) or littermate controls (VE-F; 
Ppap2bf/+ Cdh5(PAC)-CreERT2+, Ppap2bf/+, or 
Ppap2bf/-, treated with tamoxifen at 3–4 wk 
old) were analyzed at least 4 wk after tamoxi-
fen treatment. (A) Percentage of mature 
CD4SP thymocytes among total CD4SP thy-
mocytes. (B) Total number of mature CD4SP 
thymocytes and immature CD4SP thymocytes. 
In A and B, each point represents an indi-
vidual mouse and bars show the mean. 
Graphs are a compilation of 11 experiments 
with a total of 14 mice per group. (C) Expres-
sion of CD69 and CD62L on CD4SP thymo-
cytes. (D) The ratio of CD69 MFI of mature 
CD4SP thymocytes from littermate controls/
CD69 MFI of mature CD4SP thymocytes from 
VE- mice. Each point represents one pair of 
mice, and the bar represents the mean. The 
graph compiles 14 pairs of mice analyzed in 
11 experiments. (E) Surface S1PR1 expression 
on mature CD4SP thymocytes. The thin line 
shows staining with a control antibody. We 
saw slight down-modulation in two experi-
ments and no detectable shift in a third.  
(F) Frozen thymic sections from tamoxifen-
treated R26R-EYFP+Cdh5(PAC)-CreERT2+ mice 
were stained for CD31 to mark endothelial cells and visualized by confocal microscopy. Bars, 100 µm. The image is representative of two mice analyzed in 
two experiments. (G) YFP expression by disaggregated thymic cell populations from tamoxifen-treated R26R-EYFP+Cdh5(PAC)-CreERT2+ mice was mea-
sured by flow cytometry. CD45+ cells are primarily T cells, as they were isolated by mechanical disruption. Each point represents an individual mouse, and 
bars show the mean. The graph compiles three mice analyzed in three experiments.
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LPP3 expres-
sion by en-
dothelial cell 
lines is in-
creased upon 
exposure to stimuli including VEGF and TNF (Humtsoe et al., 
2003; Wary and Humtsoe, 2005; Senda et al., 2009), and 
LPP3 expression by epithelial lines is increased upon expo-
sure to stimuli including EGF (Kai et al., 1997; Humtsoe 
et al., 2003). We propose that S1P levels could be rapidly 
increased in response to physiological signals, not only by 
increasing phosphorylation of sphingosine but also simply by 
inhibiting degradation. This may be one reason that a ubiq-
uitous lipid evolved to be a signaling molecule.
One question raised by these findings is what is the nor-
mal spatial distribution of S1P within the thymus and how is 
it altered in the absence of LPP3? On average, extracellular 
S1P is lower in the thymus than in circulation (Schwab and 
Cyster, 2007), but whether there are local variations remains 
unknown. For example, whether a gradient of S1P guides 
T cells toward egress structures or whether T cells encounter 
S1P only as they probe the blood vessels is an open question. 
We hypothesize that in the absence of LPP3 in epithelial cells, 
which form a network throughout the thymus, S1P increases 
widely in the tissue, masking local S1P gradients and desensi-
tizing T cells to remaining egress cues. In the absence of LPP3 
in endothelial cells, S1P may increase only proximal to blood 
vessels. Although the loss of LPP3 in endothelial cells has a 
the simplest interpretation of our data is that LPP3 is func-
tioning to limit thymic S1P.
This is the first time to our knowledge that a phospha-
tase has been implicated in lymphoid organ S1P regulation 
in vivo. The Drosophila melanogaster homologues of LPP3, 
wunen and wunen2, are required to guide germ cell migra-
tion in the developing embryo. Germ cells and the sur-
rounding tissue compete for hydrolysis of a lipid phosphate, 
although the identity of this lipid is unknown (Renault and 
Lehmann, 2006). Ppap2b/ mice die at or before embry-
onic day 10.5 with failure to form a chorioallantoic placenta 
and yolk sac vasculature (Escalante-Alcalde et al., 2003). It is 
not known whether this phenotype is the result of an imbal-
ance in phospholipids and, if so, which phospholipid, or 
whether it is the result of a phosphatase-independent func-
tion of LPP3 (Humtsoe et al., 2003). Ppap2bf/fNestin-Cre+ 
mice have increased S1P in the cerebellum (López-Juárez 
et al., 2011). LPP3 is needed on both endothelial and epithe-
lial cells, revealing a novel role of epithelial cells in enabling 
thymic egress.
We further found that although LPP1 and LPP2 have a 
similar expression pattern to LPP3, and S1P lyase and SPP1 
are widely expressed in the thymus, they cannot compensate 
for the loss of LPP3. Moreover, deletion of LPP3 in either 
epithelial cells or endothelial cells is sufficient to cause an 
increase in thymic S1P and an egress block. These observa-
tions suggest that S1P generation and destruction are finely 
balanced. Little is known about LPP3 regulation, although 
Figure 6. LPP3 expression by epithelial cells is 
required to maintain low thymic SP. Mice in 
which LPP3 was deleted by Keratin14-Cre (TEC-; 
Ppap2bf/Krt14Cre+) or littermate controls (TEC-F; 
Ppap2bf/+Krt14Cre+, Ppap2bf/+, or Ppap2bf/) were 
analyzed at 6 wk or older. (A) Percentage of mature 
CD4SP thymocytes among total CD4SP thymocytes. 
(B) Total number of mature CD4SP thymocytes and 
immature CD4SP thymocytes. In A and B, each point 
represents an individual mouse and bars show the 
mean. Graphs compile 11 experiments with a total of 
13 mice per group. (C) Expression of CD69 and 
CD62L on CD4SP thymocytes. (D) The ratio of CD69 
MFI of mature CD4SP thymocytes from littermate 
controls/CD69 MFI of mature CD4SP thymocytes 
from TEC- mice. Each point represents one pair of 
mice and the bar represents the mean. The graph 
compiles 13 pairs of mice analyzed in 11 experi-
ments. (E) Surface S1PR1 expression on mature 
CD4SP thymocytes. Thin line shows staining with a 
control antibody. Data are representative of three 
pairs of mice analyzed in three experiments. (F) Fro-
zen thymic sections from R26R-EYFP+Krt14Cre+ mice 
were stained for EpCAM to mark epithelial cells and 
CD8 to distinguish the cortex from the medulla and 
visualized by confocal microscopy. Bar, 100 µm.  
Image is representative of two mice in two experi-
ments. (G) YFP expression by disaggregated thymic 
cell populations from R26R-EYFP+Krt14Cre+ mice 
was measured by flow cytometry. CD45+ cells are 
primarily T cells, as they were isolated by mechanical 
disruption. Each point represents an individual 
mouse and bars show the mean. The graph compiles 
two mice analyzed in two experiments.
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intestine, and skin and may be an attractive target to manipu-
late S1P selectively in these organs. The observation that S1P 
levels are very tightly regulated offers the hope that highly 
specific drugs can be developed to manipulate S1P signaling, 
lymphocyte trafficking, and inflammation.
MATERIALS AND METHODS
Mice. Ppap2bf/f (Escalante-Alcalde et al., 2007), R26R-EYFP (Srinivas et al., 
2001), Rag2p-GFP (Yu et al., 1999), Mx1-Cre (Kühn et al., 1995), Keratin 
14-Cre (Dassule et al., 2000), FoxN1-Cre (Gordon et al., 2007), Tie2-Cre 
(Kisanuki et al., 2001), and Cdh5(PAC)-CreERT2 (Wang et al., 2010) mice 
have been previously described. CD45.2+ B6 and CD45.1+ congenic B6 
mice were obtained from the National Cancer Institute.
To induce deletion by Mx1-Cre, 3–5-d-old mice received a single intra-
peritoneal injection with 50–100 µl pI-pC (Midland Scientific) at a concen-
tration of 10 mg/ml in sterile PBS. To induce deletion by VE-Cadherin 
CreERT2, 3–4-wk-old mice received three intraperitoneal injections on 
three consecutive days with 50 µl tamoxifen (Sigma Aldrich) at a concentra-
tion of 20 mg/ml in maize oil.
Mice were housed in specific pathogen-free conditions at the Skirball 
Institute animal facility. All animal experiments were performed in accor-
dance with protocols approved by the New York University Institutional 
Animal Care and Use Committee.
BM chimeras, BrdU labeling, intrathymic injection, and deoxypyri-
doxine treatment. For BM chimeras, recipients were lethally irradiated by 
two 6.5 Gray doses of  irradiation from a cesium source separated by 3 h 
and received 2–10 × 106 BM cells by intravenous injection. Chimeras were 
analyzed at least 7 wk after transplantation. For BrdU labeling, 0.8 mg/ml of 
BrdU (Sigma-Aldrich) was added to the drinking water and changed daily.
For intrathymic injection, mice were anesthetized with 4% isoflurane in 
medical air and maintained under anesthesia using a nose cone with 1.5% 
isoflurane in medical air. Hair was removed from the thorax using depilatory 
cream, and animals were placed on a heat pad for the injection. Thymus visu-
alization was performed in real time using a 30-MHz 707B ultrasound probe 
(VisualSonics). The injection needle (Hamilton syringe with 30-gauge nee-
dle) was mounted on a 3D micromanipulator and the tip of the needle placed 
in the imaging plane. 20 µl (10 µl in each lobe) sulfo-NHS biotin (Thermo 
Fisher Scientific) at a concentration of 5 mg/ml in PBS was injected. For 
4-deoxypyridoxine-HCl (DOP) treatment, 30 mg/liter DOP (Sigma-Aldrich) 
and 10 g/liter sucrose (to overcome taste aversion) were added to the drink-
ing water. Control mice received drinking water with 10 g/liter sucrose.
Cell preparation. Lymphocytes were isolated by mechanical disruption and 
filtration through a 70-µm cell strainer and enumerated with a cell counter 
(Z1 Particle Counter; Beckman Coulter) set to detect nuclei between 3.5 and 
7 µm. Thymic stromal cells were isolated as previously described (Gray et al., 
2002). In brief, the thymus was diced into small pieces and rotated for 30 min 
at 4°C in RPMI 1640 supplemented with 10 mM Hepes (RPMI/H). The su-
pernatant containing lymphocytes was removed, the remaining fragments were 
briefly agitated in ice cold RPMI/H, the supernatant containing lymphocytes 
was removed, the fragments were briefly agitated once more in ice-cold 
RPMI/H, and the supernatant containing lymphocytes was removed. The re-
maining fragments were subjected to three successive digestions for 15 min at 
37°C in RPMI/H containing Blendzyme III (Roche) at 0.14 U/ml and DNase 
I at 1 mg/ml. In the middle and at the end of the first digestion, the fragments 
were disaggregated with a Pasteur pipette and the supernatant was discarded. 
In the middle and at the end of the second digestion, the fragments were dis-
aggregated with a 22-gauge needle. In the middle and at the end of the third 
digestion, the fragments were disaggregated with a 26-gauge needle. The 
supernatants from the final two digestions and remaining fragments were 
pooled and incubated for 10 min on ice in PBS 1% FBS 5 mM EDTA to yield 
a mixture enriched in stromal cells. Cells were stained and analyzed using a 
FACSCalibur (BD) or LSRII (BD) or sorted using a MoFlo (Beckman Coul-
ter) or FACSAria (BD). Data were analyzed using FlowJo (v. 8.8.1; Tree Star).
minimal effect on average T cell S1PR1, it may desensitize 
T cells to S1P just where they most need a sharp gradient to 
cross into circulation. LPP3 is also expressed by other stromal 
cells, likely including pericytes. Whether S1P is regulated dif-
ferently in the thymic parenchyma, at the border with blood, 
and in the perivascular space warrants further investigation.
A second, related, question raised by these findings is what 
is the source of S1P that LPP3 destroys? LPP3 may be respon-
sible for destroying excess S1P made intracellularly during 
membrane sphingolipid metabolism and secreted at some 
rate. LPP3 may also prevent plasma S1P from entering tissues. 
Vascular endothelial cells sit at the boundary of the high S1P 
environment of the blood and the low S1P environment of 
the tissue, and endothelial LPP3 may prevent S1P from cross-
ing the blood vessel wall. Hematopoietic cells, particularly 
erythrocytes, are the major source of plasma S1P, but endo-
thelial cells themselves may also contribute (Pappu et al., 2007; 
Hla et al., 2008; Venkataraman et al., 2008). Blood vessel en-
dothelial cells efficiently secrete S1P in culture (Venkataraman 
et al., 2008), and lymphatic endothelial cells are the main 
source of lymph S1P (Pham et al., 2010). Intriguingly, LPP3 
has been shown to localize to the basolateral side of cultured 
MDCK cells (Jia et al., 2003), and our LPP3 antibody stain 
seems to ring blood vessels. The subcellular organization of 
S1P metabolic enzymes may enable vascular endothelial cells 
to play a dual role in S1P generation and destruction. Thymic 
vessels are unique in that they have a double-walled structure 
with vascular endothelial cells surrounded by epithelial cells 
(Ushiki, 1986; Kato, 1997; Ushiki and Takeda, 1997; Mori 
et al., 2007), so a requirement for LPP3 in epithelial cells is 
also consistent with a role in destroying plasma S1P.
Although our original hypothesis was that LPP3 is destroy-
ing metabolic or plasma S1P, it is also possible that LPP3 is re-
sponsible for preventing the spread of S1P made and secreted 
for a highly localized signaling. Like vascular endothelial cells, 
epithelial cells express high levels of the S1P generating en-
zyme sphingosine kinase 1 (unpublished data). A role for S1P 
production by thymic epithelial cells has not been shown, al-
though many are plausible. Epithelial cell S1P secretion may 
facilitate T cell egress, leading them across the first basement 
membrane of the double-walled vessels. This would be analo-
gous to the role of pericytes, which sit in the perivascular 
space and whose S1P secretion promotes exit (Zachariah and 
Cyster, 2010). Epithelial cell S1P may affect T cell motility or 
shape T cell maturation; T cell S1PR1 has been shown to in-
hibit development of regulatory T cells (Liu et al., 2009), but 
the source of S1P within the thymus has not been identified. 
Finally, it is tempting to speculate that S1P may play a more 
general role in epithelial cell junctions, analogous to its role in 
endothelial barrier function. In this regard, it is interesting to 
note that LPP3 was first cloned in an attempt to identify genes 
required for intestinal epithelial cell differentiation (Barilà 
et al., 1996). Currently there are no techniques to measure 
changes in extracellular S1P in nonlymphoid tissues, but 
LPP3 may play a role in regulating not only thymic S1P but 
also S1P in heavily epithelial tissues, such as the lung, small 
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Online supplemental material. Fig. S1 shows the effect of LPP3 deletion 
on the numbers of DN and DP T cells in the thymus, that LPP3 deletion is 
associated with reduced numbers of CD4 T cells in LNs and spleen, and that 
LPP3 deletion inhibits egress of mature CD8 T cells from the thymus. Fig. S2 
shows that LPP3 deletion does not detectably alter S1pr1 transcript in mature 
thymocytes or surface CCR7 expression on mature thymocytes, and that an 
increase in total thymic S1P is not detectable by mass spectrometry. Fig. S3 
shows that chimeras generated with LPP3-deficient BM do not have elevated 
thymic S1P and that inhibition of S1P lyase further increases thymic S1P in 
LPP3-deficient mice. Fig. S4 shows expression of LPP3 and the pericyte 
marker PDGFR- by confocal microscopy. Fig. S5 shows specificity of dele-
tion by Cdh5(PAC)-CreERT2 and a reduction in the number of T cells in the 
periphery of Ppap2bf/Cdh5(PAC)-CreERT2+ mice. Fig. S6 shows specificity 
of deletion by Krt14-Cre, a reduction in the number of T cells in the pe-
riphery of Ppap2bf/Krt14-Cre+ mice, and an accumulation of mature T cells 
in the thymus of Ppap2bf/Foxn1Cre+ mice. Online supplemental material is 
available at http://www.jem.org/cgi/content/full/jem.20102551/DC1.
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Quantitative RT-PCR. Total RNA was extracted from sorted cell popula-
tions using TRIZOL (Invitrogen) according to the manufacturer’s instruc-
tions. Before RT, RNA was treated with DNase I (Invitrogen). The RNA 
was converted to cDNA with the Superscript III First Strand Synthesis Sys-
tem (Invitrogen) or the USB First-Strand cDNA Synthesis kit (Affymetrix) 
according to the manufacturer’s instructions, using a mix of oligo dT and 
random hexamers as primers. Real-time quantitative PCR was performed 
on an iCycler using iQ SYBR Green Supermix (Bio-Rad Laboratories) ac-
cording to the manufacturer’s instructions. To control for DNA contami-
nation, primers were designed to span a large intron when possible, and a 
reaction without reverse transcription was performed in parallel for each 
sample/primer pair. To control for nonspecific amplification, the size of the 
reaction products was analyzed by agarose gel electrophoresis. All primer pairs 
were tested for linear amplification over two orders of magnitude. Prim-
ers used were the following: Hprt sense, 5-AGGTTGCAAGCTTGCT-
GGT-3; Hprt antisense, 5-TGAAGTACTCATTATAGTCAAGGGCA-3; 
S1pr1 sense, 5-AGACCCAGAGTCCTG-3; S1pr1 antisense, 5-GCGA-
GCAATCCAATG-3; Ppap2b sense, 5-GGTGGCCTGCTGCATAGT-
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Sgpp1 sense, 5-GGCGCATATTTGTAAGTTTGG-3; Sgpp1 antisense, 
5-TTCTATCCTGGATGTCATTGCT-3; Sgpp2 sense, 5-TGTCTCAG-
CAGACTCTACAC-3; Sgpp2 antisense, 5-GAGTCCAGGGAATCGAT-
GAG-3; Spgl1 sense, 5-TATTGCACCAAATATGAGCC-3; and Spgl1 
antisense, 5-CTGTTGTTCGATCTTACGTC-3.
Antibodies. S1PR1-specific antibody and control were previously de-
scribed (Lo et al., 2005). Some stainings were done with a second batch of 
antiserum made in the same way and tested for specificity. In this case, a 
polyclonal rabbit anti-GST antibody (Bethyl Laboratories, Inc.) was used as 
a control. LPP3-specific antibody and staining technique were previously 
described (López-Juárez et al., 2011).
Fluorochrome- or biotin-conjugated anti-CCR7 (clone 4B12), CD4 
(clone RMA4-5 or GK1.5), CD8 (clone 53–6.7), CD19 (clone 6D5), CD31 
(clone MEC13.3 for immunohistology, clone 390 for flow cytometry), CD44 
(clone IM7), CD45 (clone 30F11), CD45.1 (clone A20), CD45.2 (clone 
104), CD62L (clone MEL14), CD69 (clone H1.2F3), CXCR4 (clone 2B11), 
EpCAM (clone G8.8), NK1.1 (clone PK136), CD25 (clone PC61), and 
TCR- (clone GL3) were purchased from BioLegend, eBioscience, or BD. 
Biotin-conjugated polyclonal anti–PDGFR- was purchased from R&D 
Systems. Intracellular staining for BrdU was done using the BD FITC BrdU 
Flow kit according to the manufacturer’s instructions.
Flow cytometry and confocal imaging. Flow cytometry was done using 
standard conditions. All staining was performed on ice, except for CCR7 
staining which was at 37°C. Staining for S1PR1 was done with 0.05% so-
dium azide in all buffers.
Confocal imaging was done using standard conditions. In brief, the thy-
mus was excised, fixed overnight at 4°C in periodate-lysine-paraformalde-
hyde medium (PLP; 0.05 M phosphate buffer, pH 7.4, 0.1 M L-Lysine, 10 mg/ml 
paraformaldehyde, and 2 mg/ml NaIO4) and progressively dehydrated at 4°C 
in sucrose (10, 20, and 30% in PBS). Tissues were snap frozen in OCT com-
pound (Tissue-Tek; Sakura). 10-µm-thick tissue sections were rehydrated 
(rehydration and staining buffer was PBS with 4% mouse serum, 4% rat se-
rum, 1% Triton X-100, and 0.1 M Tris), stained, and imaged using a confocal 
microscope (LSM510; Carl Zeiss) with a 40× oil immersion objective. 
Images were processed using ImageJ software (version 1.41; National Institutes 
of Health).
Mass spectrometry. Before taking thymus, mice were perfused with 10 ml 
PBS. Samples were snap frozen in liquid nitrogen and stored at 80°C. Lipids 
were purified and mass spectrometry was performed as previously described 
(López-Juárez et al., 2011).
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